Valneva jumped more than 33% in morning trading.

Tiger Newspress2021-10-18

Valneva SE(NASDAQ:VALN) jumped more than 33% in morning trading.

The company’s COVID-19 vaccine elicits a robust immune response with far fewer side effects than the Oxford/AstraZeneca plc's (NASDAQ:AZN) jab, according to Phase 3 trial results.

Valneva said its latest trial included around 4,000 participants aged 18 and older across 26 trial sites.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

发表看法
2